Treat-and-extend protocol for AMD improves visual acuity, eases treatment burden

A treat-and-extend anti-VEGF treatment regimen for neovascular age-related macular degeneration yielded visual outcomes similar to those of the ANCHOR and MARINA studies. The prospective study included 120 patients with subfoveal choroidal neovascularization secondary to AMD. Patients received three initial monthly injections of Lucentis 0.5 mg (ranibizumab, Genentech) or Avastin 1.25 mg (bevacizumab, Genentech). Eyes with signs of CNV, a five-letter loss of visual acuity or persistent hemorrhage subsequently received injections every 4 weeks until signs of CNV activity ceased.

Full Story →